Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | PPP5C | P53041 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.42 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508546 | 1.00 | TDP1 (0.62) | TDP1CYP1A2HTR1APHGDHMGLL | |
| Hydrochloric Acid SCHEMBL29238555 | 0.97 | TDP1 (0.59) | TDP1CYP1A2HTR1APHGDHMGLL | |
| Hydrochloric Acid SCHEMBL11666844 | 0.97 | TDP1 (0.59) | TDP1CYP1A2HTR1APHGDHMGLL | |
| Acetic Acid SCHEMBL1252420 | 0.95 | TDP1 (0.64) | TDP1CYP1A2HTR1APHGDHMGLL | |
| SCHEMBL166432 | 0.90 | TDP1 (0.52) | TDP1CYP1A2HTR1APOLBHTT | |
| SCHEMBL2852512 | 0.90 | HTT (0.57) | TDP1CYP1A2POLBHTTL3MBTL1 | |
| SCHEMBL5002566 | 0.90 | TDP1 (0.52) | TDP1CYP1A2HTR1APHGDHMGLL | |
| SCHEMBL16904 | 0.84 | ALDH1A1 (0.42) | TDP1CYP1A2POLBKDM4EALDH1A1 | |
| SCHEMBL28468317 | 0.84 | ALDH1A1 (0.42) | TDP1CYP1A2POLBKDM4EALDH1A1 | |
| SCHEMBL9079929 | 0.84 | ALDH1A1 (0.42) | TDP1CYP1A2POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 850 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119710705-A | Molybdenum selective etching solution | 湖北兴福电子材料股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119462594-A | Pradienolide compound and application thereof | 卫材R&D管理有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | claimed |
| CN-108473479-B | Solid state forms of pladienolide pyridine compounds and methods of use | 卫材研究发展管理有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-112368270-B | Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer | 卫材R&D管理有限公司 | 2023-10-13 | — | — | CN | claimed |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-08-15 | — | — | US | claimed |
| EP-3743421-B1 | COMPOUNDS | UNIV OXFORD INNOVATION LTD (GB) | 2023-03-29 | — | — | EP | claimed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | claimed |
| CN-114605415-A | Eszopiclone process impurity and synthetic method thereof | 江苏天士力帝益药业有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-113754593-A | BRD4 protein inhibitor and application thereof | 上海中医药大学 | 2021-12-07 | — | — | CN | claimed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | claimed |
| EP-1087951-A4 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2002023784-A2 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-03-21 | — | — | WO | claimed |
| US-6287840-B1 | PEPTIDOMIMETICS; COUPLING, DEBLOCKING; ANTIARTHRITIC, ANTITUMOR, ANTICARCINOGENIC, AND ANTIMETASTASIS AGENTS; MUSCULAR DYSTROPHY, GLOMERULONEPHRITIS, MALARIA, ALZHEIMER*S DISEASE | AXYS PHARMACEUTICALS, INC. | 2001-09-11 | — | — | US | claimed |
| WO-2001055147-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| EP-1087951-A1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065884-A1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-23 | — | — | WO | claimed |
| WO-1999055688-A1 | SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | claimed |
| US-5530121-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | claimed |
| EP-0593227-A1 | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | KRAS, NRAS, HRAS | TDP1 3395/4885CYP1A2 3851/4885HTR1A 4664/4885 |
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | TDP1 3530/4885CYP1A2 2705/4885HTR1A 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.